Although targeting SPOP in prostate cancer constitutes a considerable challenge, inhibiting downstream proteins escaping ubiquitination in SPOP mutant tumours may be more feasible, lending further credence to strategies targeting the P160 SRC family. Here, SPOP is linked to prostate carcinoma.